id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-0655-0003,FDA,FDA-2026-P-0655,"Determination FENOGLIDE (Fenofibrate) Tablets, 40 Milligrams and 120 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2026-04-30T04:00:00Z,2026,4,,,2026-04-30T17:56:39Z,2026-08390,0,0,09000064b92b7f6c
FDA-2026-P-0655-0004,FDA,FDA-2026-P-0655,Final Response,Other,Letter(s),2026-04-30T04:00:00Z,2026,4,2026-04-30T04:00:00Z,,2026-04-30T20:27:00Z,,0,0,09000064b92b88a0
FDA-2026-P-0655-0002,FDA,FDA-2026-P-0655,"Acknowledgment Letter from FDA DMB to Foley & Lardner, LLP",Other,Acknowledgement Letter/Receipt,2026-01-21T05:00:00Z,2026,1,2026-01-21T05:00:00Z,,2026-01-22T02:12:53Z,,0,0,09000064b91758a2
FDA-2026-P-0655-0001,FDA,FDA-2026-P-0655,"Citizen Petition from Foley & Lardner, LLP",Other,Citizen Petition,2026-01-21T05:00:00Z,2026,1,2026-01-21T05:00:00Z,,2026-04-30T18:44:16Z,,0,0,09000064b917589f